Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Says Bayer's Response To Essure Investigation Satisfactory; Approves Product Label

Executive Summary

FDA completed its investigation of a February 2015 trade complaint that charged clinical trial misconduct by Bayer HealthCare LLC for its controversial Essure permanently implanted birth control device, finding Bayer's response "satisfactory." The agency also approved amended labeling for the device.

Advertisement

Related Content

FDA 'Black Box' Labeling For Essure Highlights Adverse Events With Bayer Sterility Device
Six-Year Study Will Compare Bayer’s Essure With Tubal Ligation
FDA Investigating Attorney, Physician Beefs With Bayer’s Essure PMA
Essure Panel Stresses Need For Patient Follow-Up, But Stressed-Out Patients Say, ‘Recall It’
Expect Bayer To Get Heat At FDA Advisory Panel Over Essure Adverse Events, Doc Training

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

MT104102

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel